In:
Pharmacogenomics, Future Medicine Ltd, Vol. 12, No. 10 ( 2011-10), p. 1493-1501
Abstract:
Aims: To examine the safety profile of oseltamivir in children and evaluate the impact of P-glycoprotein polymorphisms on the incidence of neuropsychiatric adverse events (NPAE) in oseltamivir-treated children. Subjects & methods: This prospective cohort study was conducted in our tertiary care pediatric hospital (University Hospitals of Geneva, Switzerland) during the H1N1 pandemia, between 1 October 2009 and 31 January 2010. All newborn to 18 year-old patients presenting at the emergency department with a flu-like illness were eligible for inclusion. Adverse events were systematically recorded by pediatricians and/or by parents at home using a diary card, with a 30-day follow-up period. The causality assessment of oseltamivir in NPAE was performed by two clinical pharmacologists. After informed consent, enrolled patients were also genotyped for ABCB1 3435C 〉 T (rs1045642) and 2677G 〉 T/A (rs2032582) polymorphisms. Results: Among the 42 H1N1-infected, oseltamivir-treated children who were genotyped for ABCB1 3435C 〉 T and 2677G 〉 T/A variants, 36% presented NPAE. When examining the association between the diplotype and the development of NPAE, we observed that the frequency of NPAE displayed a ‘genotype-trend effect’ with the variant and the wild-type subgroups at the two far ends. A total of 11% of the 2677GG–3435CC individuals (wild-type homozygous) presented NPAE, compared with 39% of the individuals being heterozygous for at least one variant allele and 67% of the 2677TT–3435TT individuals (homozygous variants) (p = 0.149, nonsignificant). Conclusion: These observations suggest a potential influence of ABCB1 polymorphisms in oseltamivir-related NPAE, maybe as a result of an enhanced permeability of the blood–brain barrier to oseltamivir. Original submitted 26 April 2011; revision submitted 30th June 2011
Type of Medium:
Online Resource
ISSN:
1462-2416
,
1744-8042
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2011
SSG:
15,3
